Fig. 4From: Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer’s perspectiveCEAC showing the likelihood of afatinib being cost-effective compared to pemetrexed-cisplatin across different WTP thresholds. CEAC: cost-effectiveness acceptability curve; WTP: willingness to payBack to article page